Pfizer unveils what the company's structure will look like after it swallows up Wyeth. According to the Wall Street Journal, Pfizer will be splitting its research and development efforts in two: the small molecule section will be overseen by Pfizer's current R&D chief Martin Mackay, and the biologic section will be led by Wyeth's R&D chief Mikael Dolsten. "Creating two distinct, but complementary, research organizations, led by the top scientist from each company, will provide sharper focus, less bureaucracy and clearer accountability in drug discovery," Pfizer CEO Jeffrey Kindler said in a news release.
The New Monolith
Apr 08, 2009